Inflammatory bowel disease (IBD) has become a common ailment in China in the past decade. At present, the level of diagnosis and treatment of inflammatory bowel disease in China still falls behind Western countries, while the incidence increases rapidly. Chinese IBD Working Group made a new consensus on diagnosis and treatment of inflammatory bowel disease in 2012. This article is to interpret some key issues in the consensus.
China ; Humans ; Inflammatory Bowel Diseases ; diagnosis ; therapy

Child ; Humans ; Inflammatory Bowel Diseases ; diagnosis ; therapy

Malnutrition is common in patients with inflammatory bowel disease(IBD). The therapeutic role of nutrition has attracted more and more attention in the development of IBD. In recent years, researches have demonstrated that nutrition support has its unique advantages in improving patients nutritional status and reducing adverse events, and it has been recommended as the first line therapy in children with active Crohn disease. Since there are no standardized guidelines of nutritional support therapy worldwide, this article is to review the relationship between nutrition and IBD, the choice of nutritional therapy mode, the duration of the nutritional treatment and evaluation of therapeutic effects based on Expert Consensus on Nutrition Support Therapy of Inflammatory Bowel Disease (2013·Shenzhen).
Child ; Humans ; Inflammatory Bowel Diseases ; therapy ; Nutritional Status ; Nutritional Support

Anemia is a common and severe complication in inflammatory bowel disease. Anemia can induce impaired cardiovascular and renal functions, and lead to a significantly decreased quality of life. This review is dedicated to explain the underlying mechanism, diagnosis and management of anemia in inflammatory bowel disease.
Anemia ; diagnosis ; etiology ; therapy ; Humans ; Inflammatory Bowel Diseases ; complications

Anemia is a frequent and serious complication in patients with inflammatory bowel disease (IBD). One third of patients with inflammatory bowel disease suffers from recurrent anemia. Anemia is associated with a decrease in the quality of life and an increased rate of hospitalization. A number of studies have been conducted and the most relevant conclusions obtained are:(1)anemia is quite common in IBD; (2)although in many cases anemia parallels the clinical activity of the disease, many patients in remission have anemia, and iron, vitamin B12 and/or folic acid deficiency;(3)anemia, and also iron deficiency without anemia, have important consequences in the clinical status and quality of life of the patients;(4)oral iron supplement is limited by poor absorption, intolerance, and induction of oxidative stress at the site of bowel inflammation; (5) intravenous iron sucrose has a high efficiency and a significant improvement in the quality of life; (6)erythropoietin is needed in a significant number of cases to achieve normal hemoglobin levels. Combination therapy with erythropoietin leads to a faster and larger hemoglobin increase. Thus, clinicians caring for IBD patients should have a comprehensive knowledge of anemia, and apply recently published guidelines in clinical practice.
Anemia ; diagnosis ; etiology ; therapy ; Humans ; Inflammatory Bowel Diseases ; complications

Inflammatory bowel disease is a recurrent chronic intestinal inflammatory disease with unknown etiology and no effective treatment. Phosphodiesterase (PDE) regulates a variety of physiological and pathophysiological processes by mediating the hydrolysis of intracellular second messengers cyclic adenosine monophosphate and cyclic guanosine monophosphate. In recent years, a series of researches suggest that PDE inhibitors such as several PDE4 inhibitors, PDE5 inhibitors (sildenafil, tadalafil and vardenafil), PDE3 inhibitors (cilostazol), PDE9 inhibitor (PF-04447943) and PDE3/PDE4 double inhibitor (pumafentrine) have ameliorating effect on experimental colitis in animals. In clinical trials, PDE4 inhibitor apremilast showed more therapeutic advantage than tetomilast. This article reviews the recent research progress of PDE inhibitors in treatment of inflammatory bowel disease.
Animals ; Colitis ; Inflammatory Bowel Diseases/drug therapy* ; Phosphodiesterase 4 Inhibitors

Humans ; Inflammatory Bowel Diseases/drug therapy* ; Interleukin-6/therapeutic use*

The gut is an immune-microbiome-epithelial complex. Gut microbiome-host interactions have widespread biological implications, and the role of this complex system extends beyond the digestion of food and nutrient absorption. Dietary nutrients can affect this complex and play a key role in determining gut homeostasis to maintain host health. In this article, we review various dietary nutrients and their contribution to the pathogenesis and treatment of various intestinal diseases including inflammatory bowel disease, irritable bowel syndrome, colorectal cancer, and diverticulitis, among other such disorders. A better understanding of diet-host-gut microbiome interactions is essential to provide beneficial nutrients for gut health and to limit nutritional hazards to ensure successful nutritional management of gastrointestinal conditions in clinical practice.
Absorption ; Colorectal Neoplasms ; Diet ; Digestion ; Diverticulitis ; Gastrointestinal Microbiome ; Homeostasis ; Inflammatory Bowel Diseases ; Intestinal Diseases ; Irritable Bowel Syndrome ; Microbiota ; Nutrition Therapy

Traditional medications used for treating autoimmune diseases often come with a wide range of adverse effects. Current treatments focus mainly on symptom management, resulting in significant health issues and financial burdens for patients. Recently, clinical research has demonstrated the potential of helminths and their derivatives as effective therapies for autoimmune disorders. Helminths, being a near-natural immunomodulator, exhibit milder effects than broad-spectrum immunosuppressants and corticosteroids, thereby presenting a promising alternative for the treatment of autoimmune diseases. However, different helminths' therapeutic efficacy and mechanisms and their derivatives in treating autoimmune diseases may vary. Therefore, we aim to review recent clinical advancements in the use of helminths and their derivatives for treating inflammatory bowel disease, multiple sclerosis, and autism spectrum disorder, with a view to offering novel clinical treatment approaches.
Animals ; Humans ; Autism Spectrum Disorder ; Autoimmune Diseases/drug therapy* ; Helminths ; Inflammatory Bowel Diseases

OBJECTIVETo provide scientific foundations for clinical and acupoints researches on acupuncture for treatment of inflammatory bowel diseases.

METHODSReview the correlated documents of clinical experimental researches issued from 1995 to 2005, and the clinical and experimental documents about remedy of inflammatory bowel diseases by acupuncture and moxibustion were summarized and analyzed.

RESULTSAcupuncture and moxibustion had significant therapeutic effects on inflammatory bowel diseases, and the studies on the mechanisms have achieved some progresses, but the designs and the methods of these studies need to be improved.

CONCLUSIONAfterwards, the specificity of acupoints, and factors of influencing the specificity should be studied via effective diseases treated with acupuncture and moxibustion, so as sum up common regularity, rich and develop the theory about specificity of acupoints to guide clinical treatment of acupuncture and moxibustion.